Clinical Trial Update: Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

View source ↗

Summary

A clinical trial registry entry describes evaluating the combined effect of an Hsp90 inhibitor with HDAC and proteasome inhibitors on lung cancer and ER-Golgi h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• HDAC inhibitor (unspecified)
• Hsp90 inhibitor (unspecified)
• Proteasome inhibitor (unspecified)

Snippet

Sponsor: Meir Medical Center | Conditions: The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined. | Status: UNKNOWN